Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade

Area of Science:

• Immunology
• Cancer Biology
• Genetics

Background:

• Resistance to PD-1 blockade therapy poses a significant clinical challenge.
• Genetic mutations in JAK1, JAK2, and B2M can lead to acquired resistance.
• Understanding these resistance mechanisms is crucial for developing effective treatment strategies.

Purpose of the Study:

• To develop and characterize genetic models of acquired resistance to PD-1 blockade.
• To identify mechanism-based combination therapies to overcome this resistance.
• To elucidate the immunological pathways involved in restoring anti-tumor activity.

Main Methods:

• Gene knockout was used to create JAK1, JAK2, and B2M loss-of-function models in human and murine cell lines.
• Resistance to PD-1 therapy was assessed both in vitro and in vivo.
• Combination therapies involving intratumoral Toll-like receptor 9 agonists and bempegaldesleukin were tested.

Main Results:

• JAK1/2 knockout models showed resistance to interferon-induced anti-tumor effects.
• B2M knockout models were resistant to T-cell-mediated cytotoxicity due to impaired antigen presentation.
• JAK1/2 resistance was overcome by combining anti-PD-1 with TLR9 agonists, activating NK and CD8 T cells.
• B2M resistance was overcome by bempegaldesleukin, activating NK and CD4 T cells.

Conclusions:

• Mechanistically designed combination therapies can overcome genetic resistance to PD-1 blockade.
• Activating interferon signaling and stimulating NK cells are key to overcoming resistance.
• These strategies hold promise for improving PD-1 blockade efficacy in the clinic.